Guardant Health (NASDAQ:GH) Shares Gap Up Following Analyst Upgrade

Posted by on Jul 3rd, 2026

Guardant Health, Inc. (NASDAQ:GH – Get Free Report)’s share price gapped up before the market opened on Wednesday after Sanford C. Bernstein raised their price target on the stock from $175.00 to $200.00. The stock had previously closed at $150.03, but opened at $160.76. Sanford C. Bernstein currently has an outperform rating on the stock. Guardant Health shares last traded at $160.6090, with a volume of 846,171 shares.

A number of other analysts have also issued reports on the stock. Guggenheim lifted their price objective on shares of Guardant Health from $135.00 to $160.00 and gave the company a “buy” rating in a research note on Monday. UBS Group set a $150.00 price target on shares of Guardant Health in a report on Wednesday, June 24th. Mizuho lifted their price target on shares of Guardant Health from $135.00 to $175.00 and gave the stock an “outperform” rating in a research note on Monday, June 8th. The Goldman Sachs Group began coverage on shares of Guardant Health in a report on Friday, June 5th. They issued a “buy” rating and a $165.00 price objective on the stock. Finally, JPMorgan Chase & Co. upped their price objective on shares of Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Guardant Health has a consensus rating of “Moderate Buy” and an average target price of $147.32.

Check Out Our Latest Report on GH

Insider Buying and Selling at Guardant Health

In related news, CEO Amirali Talasaz sold 143,028 shares of Guardant Health stock in a transaction on Monday, June 29th. The shares were sold at an average price of $151.54, for a total value of $21,674,463.12. Following the completion of the sale, the chief executive officer owned 1,881,336 shares in the company, valued at approximately $285,097,657.44. The trade was a 7.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Musa Tariq sold 1,951 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $131.16, for a total transaction of $255,893.16. Following the transaction, the director directly owned 11,048 shares of the company’s stock, valued at approximately $1,449,055.68. This represents a 15.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 712,513 shares of company stock valued at $90,921,587. Corporate insiders own 5.60% of the company’s stock.

Institutional Trading of Guardant Health

Hedge funds and other institutional investors have recently bought and sold shares of the company. V Square Quantitative Management LLC acquired a new position in shares of Guardant Health in the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC acquired a new stake in shares of Guardant Health during the 4th quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Guardant Health during the fourth quarter worth $31,000. Elyxium Wealth LLC bought a new position in Guardant Health during the fourth quarter worth $35,000. Finally, Parallel Advisors LLC boosted its holdings in Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares during the period. 92.60% of the stock is owned by institutional investors.

Guardant Health Price Performance

The business’s fifty day simple moving average is $118.33 and its 200 day simple moving average is $105.66. The stock has a market cap of $22.27 billion, a price-to-earnings ratio of -49.55 and a beta of 1.59.

Guardant Health Company Profile

(Get Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

Read More

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.